GO
Loading...

Drug Retail

More

  • Problems for potpreneurs  Wednesday, 24 Sep 2014 | 1:54 PM ET

    CNBC's Kate Rogers reports on the uphill battle facing potpreneurs.

  • Tekmira soars on FDA news  Monday, 22 Sep 2014 | 2:05 PM ET

    Tekmira said regulators in the U.S. and Canada authorized use of its experimental drug for Ebola through an expanded access program. CNBC's Meg Tirrell provides insight.

  • High at work  Thursday, 18 Sep 2014 | 1:54 PM ET

    A new survey from Mashable finds nearly 10 percent of Americans admit to smoking pot before heading into the office. CNBC's Kate Rogers shares the difficulties in testing employees.

  • Sept 18- Rite Aid Corp cut its full-year profit forecast for the second time in about three months due to lower margins in its pharmacy business, sending its shares down more than 16 percent.

  • Sept 18- Rite Aid Corp, the third-largest U.S. drugstore chain, cut its full-year profit forecast for the second time, citing lower margins in its pharmacy business, sending its shares down 11 percent in premarket trading.

  • Rite Aid cuts full-year profit forecast for second time Thursday, 18 Sep 2014 | 7:27 AM ET

    Sept 18- Rite Aid Corp, the third largest U.S. drugstore chain, cut its full-year profit forecast for the second time this year as lower margins from its pharmacy business continue to eat into earnings. Rite Aid shares fell nearly 9 percent in premarket trading on Thursday after the company also shaved the top end of its sales forecast.

  • Avanir up on Alzheimer's trial  Monday, 15 Sep 2014 | 1:03 PM ET

    Avanir Pharma is up more than 60 percent, after the company said its drug was more effective in reducing agitation associated with Alzheimer's, compared with a placebo. CNBC's Meg Tirrell speaks to the company's CEO Keith Katkin.

  • Orexigen's obesity pill  Thursday, 11 Sep 2014 | 1:11 PM ET

    Orexigen's obesity pill is called Contrave, and it's been approved in the U.S. CNBC's Meg Tirrell reports.

  • Food prices hit 4-year low, Russia ban hurts Thursday, 11 Sep 2014 | 8:20 AM ET

    The UN food price index has dipped to a four-year low as good weather has resulted in an oversupply of cereals and dairy imports have slowed.

  • Walgreen adds activist hedge fund founder to board Monday, 8 Sep 2014 | 7:57 AM ET
    Barry Rosenstein, founder and managing partner of Jana Partners

    Walgreen is naming Jana founder Rosenstein to its board and the activist investor will get a say in choosing at least one additional director.

  • Big change for pain drugs  Friday, 22 Aug 2014 | 2:12 PM ET

    CNBC's Meg Tirrell reports the Drug Enforcement Administration is changing the rules around pain drugs like Vicodin. The drugs will be deemed "schedule 2 substances," versus the less restrictive "schedule 3."

  • Obesity treatment sales fall short  Monday, 18 Aug 2014 | 6:26 AM ET

    CNBC's Meg Tirrell provides insight to the definition of obesity by the CDC, and which drug companies are working on treatments in the space.

  • Forest fire threatens illegal marijuana grows  Thursday, 14 Aug 2014 | 1:29 PM ET

    A massive fire in Northern California has so far burned close to 12,000 acres and injured 12 people. CNBC's Jane Wells reports on the costs to the state, as well as to marijuana growers.

  • Ebola not easily spread: Doctor  Thursday, 7 Aug 2014 | 3:19 PM ET

    Dr. Beth Bell, CDC Infectious Diseases Center, discusses the Ebola crisis in West Africa, and the risks to U.S. citizens. Bell explains current experimental treatments.

  • Pharma companies rush to help Ebola  Thursday, 7 Aug 2014 | 2:17 PM ET

    The CDC Director is testifying before Congress on Ebola, and pharma companies are scrambling to create drugs to help. CNBC's Meg Tirrell, and Michael Yee, RBC Capital Markets, discuss some of these companies.

  • Will generic Viagra transform China? Tuesday, 5 Aug 2014 | 6:21 PM ET

    Viagra's patent in China has expired and some analysts expect cheaper prices will bring a surge of demand for the storied erectile dysfunction drug.

  • The push back on Sovaldi  Friday, 25 Jul 2014 | 2:52 PM ET

    Insurance companies are hurting from the high cost of hepatitis C drug Sovaldi. Arthur Caplan, NYU Langone Medical Center, and CNBC's Bertha Coombs, share their opinions.

  • The $84,000 drug debate  Friday, 25 Jul 2014 | 2:50 PM ET

    CNBC's Bertha Coombs reports which insurance stocks are hurting from the high cost of hepatitis C Sovaldi.

  • Drug costs hit insurers: Gilead still a buy?  Friday, 25 Jul 2014 | 12:15 PM ET

    CNBC's Bertha Coombs reports which insurance stocks are feeling the pressure from high drug costs. FMHR trader Stephen Weiss advises investors to stick with Gilead.

  • FedEx indicted for prescription roulette  Friday, 18 Jul 2014 | 1:53 PM ET

    CNBC's Scott Cohn reports FedEx has been indicted on 15 criminal counts for helping Internet pharmacies deliver drugs to buyers in the U.S. without prescriptions.